Clinical Trials
3 trialsNCT05017025 2026-05-20
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03898791 2021-08-05
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03092934 2021-07-02
A Study of AK-01 (LY3295668) in Solid Tumors
Eli Lilly and Company
Phase 1/2 Completed